Filing Flows › Abbott Laboratories (ABT) › Q2 2026 › vs Q2 2025
Abbott Laboratories (ABT) Q2 2026 vs Q2 2025 (year over year)
Abbott Laboratories's revenue rose $1.5B (+13%) from $11.1B in Q2 2025 to $12.6B in Q2 2026. Operating margin 13.4% against 18.4% (-5.0 pts).
Abbott Laboratories, Q2 2026: revenue $12.6B (+13% year over year), operating margin 13.4%, net earnings $928M, operating cash flow $2.5B. The chart draws each line against Q2 2025, the increases inside each band.
Margins
| Q2 2026 | Q2 2025 | Change | |
|---|---|---|---|
| Operating margin | 13.4% | 18.4% | -5.0 pts |
| Net margin | 7.4% | 16.0% | -8.6 pts |
| Free cash flow margin | 15.8% | 13.9% | +1.9 pts |
Every line
| Line | Q2 2026 | Q2 2025 | Change | % |
|---|---|---|---|---|
| Revenue | $12.6B | $11.1B | $1.5B | +13% |
| Operating profit | $1.7B | $2.1B | −$359M | -17% |
| Costs & expenses | $10.9B | $9.1B | $1.8B | +20% |
| Pre-tax earnings | $1.5B | $2.1B | −$626M | -29% |
| Other expense, net | $169M | −$98.0M | $267M | — |
| Cost of revenue | $5.3B | $4.9B | $471M | +10% |
| Research & development | $892M | $725M | $167M | +23% |
| SG&A | $4.0B | $3.1B | $934M | +30% |
| Other operating costs | $658M | $420M | $238M | +57% |
| Net earnings | $928M | $1.8B | −$851M | -48% |
| Income tax | $596M | $371M | $225M | +61% |
| Depreciation & amortization | $1.1B | $777M | $283M | +36% |
| Share-based compensation | $168M | $142M | $26.0M | +18% |
| Working capital & other | $332M | −$651M | $983M | — |
| Operating cash flow | $2.5B | $2.0B | $441M | +22% |
| Free cash flow (OCF − capex) | $2.0B | $1.5B | $446M | +29% |
| Capital expenditures | $497M | $502M | −$5.0M | -1% |
Questions
How much did Abbott Laboratories's revenue grow year over year in Q2 2026?
Abbott Laboratories's revenue rose $1.5B (+13%) from $11.1B in Q2 2025 to $12.6B in Q2 2026. Operating margin 13.4% against 18.4% (-5.0 pts).